



PRESS RELEASE

5th December 2014, Hyderabad

Aurobindo completes the acquisition of Natrol

Aurobindo Pharma Limited (BSE:524804 and NSE:AUROPHARMA) today announced the completion of acquisition of assets of nutritional supplement maker, Natrol Inc. and other affiliate entities ("Natrol") through its wholly owned subsidiary Aurobindo Pharma USA Inc. ("APUSA"). APUSA emerged as the highest and best bidder to acquire assets of Natrol under the auction process by the United States Bankruptcy Court for the District of Delaware was previously announced on 12th November 2014.

APUSA acquired the manufacturing assets, personnel, commercial infrastructure including the well established nutraceuticals brands in USA of Natrol along with an agreement to take on certain liabilities, with a bid of US\$132.5 million. The assets have been acquired under a wholly owned subsidiary "Nature Acquisition LLC" and since changed to "Natrol LLC. The final terms of acquisition are the same as originally envisaged during announcement made earlier. APUSA expects the profitability to improve by combining the strength of both enterprises in creating a fully integrated nutraceuticals platform in the USA and other international markets.

Mesrop Khoudagoulian, Natrol CEO commented "I am pleased that Aurobindo recognizes the values of Natrol's uncompromised quality products, loyal customers, talented employees and solid relationships with our retailer partners. We look forward to working with the Aurobindo team to further expand our over-the-counter product portfolio and our reach with the financial support of strong owners."

Mr N Govindarajan, Managing Director of Aurobindo stated that: "Natrol comes with certain well established brands and an extensive distribution network consisting of retail pharmacy chains and specialty health food stores, to help us tactically position ourselves in the US nutraceuticals space and offer an effective growth strategy to expand market penetration going forward"

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

About Aurobindo Pharma USA

Aurobindo Pharma USA Inc (APUSA) based at Dayton, New Jersey, USA is committed to delivering a broad portfolio of quality, affordable generic pharmaceuticals to pharmacists and patients in USA and includes more than 125 product families and 450 individual product packages, representing a wide range of therapeutic categories. In addition to its global production, APUSA operates 2 facilities in New Jersey. Through its flexibility in balancing highly efficient global production with in-market capabilities for packaging and controlled substance development and manufacture, APUSA is diversifying into a wide range of products and dosage forms. APUSA is also in the US OTC market through its subsidiary, Aurohealth LLC to develop, manufacture, market and distribute OTC products in the US.

**About Natrol**

Natrol, Inc. manufactures and sells quality uncompromised nutritional supplements in the United States and select international markets. It offers branded products including vitamins, minerals, and supplements; diet and weight management products; sports nutrition products; products and formulas for hair, skin, and nails. Natrol's portfolio of brands includes Natrol®, MRI, Prolab®, Laci Le Beau®, Promensil®, Trinovin®, Nu Hair® and Shen Min®. The company was founded in 1980 and is headquartered in Chatsworth, California.

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited

Phone: 040-66725000 / 66725401

Email: ir@aurobindo.com

Website : www.aurobindo.com

Corporate Off: WaterMark Building, Level-1
Plot No.11, Survey No. 9
Kondapur, Hitech City, Hyderabad

Reg Off: Plot No. 2, Maitrivihar
Ameerpet, Hyderabad